Coldstream Capital Management Inc. Buys 1,274 Shares of DexCom, Inc. (NASDAQ:DXCM)

Coldstream Capital Management Inc. increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 19.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,745 shares of the medical device company’s stock after purchasing an additional 1,274 shares during the quarter. Coldstream Capital Management Inc.’s holdings in DexCom were worth $878,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of DXCM. Capital World Investors raised its holdings in DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares during the period. Norges Bank bought a new position in DexCom in the 4th quarter worth $540,178,000. Artisan Partners Limited Partnership raised its holdings in DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after purchasing an additional 3,672,471 shares during the period. Capital Research Global Investors raised its holdings in DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after purchasing an additional 2,695,296 shares during the period. Finally, Sands Capital Management LLC raised its holdings in DexCom by 10.2% in the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after purchasing an additional 1,398,136 shares during the period. 97.75% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Michael Jon Brown sold 659 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,483 shares of company stock valued at $315,258. 0.30% of the stock is currently owned by insiders.

DexCom Trading Down 0.1 %

Shares of NASDAQ DXCM opened at $68.47 on Thursday. The business’s 50 day moving average is $84.08 and its two-hundred day moving average is $111.90. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The stock has a market capitalization of $27.23 billion, a P/E ratio of 44.17, a PEG ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.34 earnings per share. As a group, research analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on DXCM shares. Piper Sandler reissued an “overweight” rating and set a $90.00 price target on shares of DexCom in a report on Monday, August 26th. Wells Fargo & Company lowered their price objective on DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research report on Friday, July 26th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Royal Bank of Canada lowered their price objective on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research report on Friday, July 26th. Finally, Stifel Nicolaus boosted their price objective on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $112.25.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.